Kunming Hope of

Company snapshot

Kunming Hope of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Elderly AML Patients, Menkes Syndrome. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1), phase 1 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Kunming Hope of. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Kunming Hope of.

1. Jun 8, 2026 Clinical update

   Recombinant adeno-associated virus administration — Phase 1

2. Jun 8, 2026 Clinical update

   Experimental: Venetoclax in combination with Decitabine (+-sorafenib) — Phase 3

View all clinical trial activity →

• What is Kunming Hope of?

  Kunming Hope of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Elderly AML Patients, Menkes Syndrome. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.g

• Is Kunming Hope of publicly traded?

  Kunming Hope of appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Kunming Hope of develop or market?

  We link 8 drug profile(s) where Kunming Hope of is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/kunming-hope-of-health-hospital#company-drugs.

• What are the latest developments for Kunming Hope of?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Kunming Hope of focus on?

  Kunming Hope of focuses on Elderly AML Patients, Menkes Syndrome based on our analysis of their pipeline programs and drug development activities.